Aminoester Derivatives for COPD Dual-Action Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) with bronchodilators and anti-inflammatory agents have limitations, including systemic side effects from muscarinic antagonists and mechanism-associated side effects from PDE4 inhibitors, which restrict their therapeutic window and effectiveness.
Innovation Solution
Development of novel compounds that act as both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, designed to provide both bronchodilating and anti-inflammatory effects while minimizing systemic side effects through targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If muscarinic antagonists are used for bronchodilation, then airflow limitation is improved, but systemic side effects such as tachycardia and dry mouth occur
Solution Approach 1:
The patent combines two distinct therapeutic mechanisms into a single dual-action compound: PDE4 inhibition (anti-inflammatory) and M3 receptor antagonism (bronchodilation). This merging allows the compound to address both the inflammatory and bronchoconstrictive components of COPD simultaneously, improving airflow while potentially reducing the need for high doses of single-agent therapies that cause systemic side effects.
Solution Approach 2:
The compound exhibits selective action at the target site (lungs) through M3 receptor antagonism for localized bronchodilation, while the PDE4 inhibition provides anti-inflammatory effects specifically in pulmonary tissues. This localized quality of action aims to maximize therapeutic benefit in the respiratory tract while minimizing systemic exposure and associated side effects.
2Object-affected harmful factors
If PDE4 inhibitors are used for anti-inflammatory effects, then inflammatory response is suppressed, but mechanism-associated side effects occur
Solution Approach 1:
By integrating PDE4 inhibition with M3 antagonism in a single molecule, the patent seeks to achieve anti-inflammatory effects at lower doses than would be required for PDE4 inhibitors alone, thereby reducing mechanism-associated side effects such as gastrointestinal disturbances and weight loss that limit PDE4 inhibitor therapy.
Solution Approach 2:
The dual-action compound represents a composite pharmacological agent that combines two different mechanism of actions (PDE4 inhibition and M3 antagonism) into one molecular entity, allowing synergistic or additive therapeutic effects while potentially reducing the dosage requirements and associated side effects of each individual mechanism.
3Ease of operation
If single-agent therapy is used, then treatment is simple, but therapeutic window is restricted due to side effects
Solution Approach 1:
The dual-action compound consolidates two therapeutic functions (bronchodilation and anti-inflammatory activity) into a single medication, maintaining treatment simplicity while expanding the therapeutic window by addressing multiple pathophysiological mechanisms of COPD simultaneously, thereby reducing the need for polypharmacy and its associated complexities.
Data Source
AI summary
Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.